19 Dec 2018
Exosome nanoparticles produced by cells may offer diagnostic and therapeutic potential that align to cellular therapies. In this video, Prof. Steve Conlan, Director of Innovation and head of the Reproductive Biology and Gynecological Oncology research group at Swansea University Medical School, discusses how the production and purification of exosomes may form a biopharmaceutical option for cancer patients in the future.
Reproductive Biology and Gynaecological Oncology, College of Medicine, Swansea University Medical School
Prof. Conlan leads Reproductive Biology and Gynecological Oncology research at Swansea University Medical School, investigating female health issues including endometrial (womb) and ovarian cancers, polycystic ovary syndrome (PCOS), endometriosis and in vitro fertilization (IVF). The team develop antibody-drug conjugates (ADC), nanoparticles drug delivery systems and exosomes for cancer treatment, biomarkers and nanosensors for disease diagnosis/monitoring, and investigate epigenetic/transcription disease mechanisms using Chromatrap™ technology co-developed by Porvair Ltd and Prof. Conlan’s group.